PATENT CLAIM ANALYSIS

Application Number: 16356373
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["424", "093210"]

Abstract:
Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.

Claim (Index 106):
The method of  claim 105 , wherein the weight ratio of gRNA to Cas9 endonuclease in the RNP is 1:1.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 99.0
- Lexical Diversity: 1.46667
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16198361', '14013250', '15927357', '16281751', '15127087']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7529092878267759
- 35 USC 102 Novelty (BERT): 0.5444868284060878
- Combined Prediction Score: 0.7320670418847071
- Mean Citation Score: 363.352222
- Max Citation Score: 384.84692
- Similarity Product: 249.05975535326004

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test